Introduction {#s1}
============

About 1% of patients with acute ischemic stroke have a basilar artery occlusion (BAO) that is amendable to endovascular treatment.[@R1] Such patients present with particularly severe symptoms and have a poor prognosis compared with those with anterior circulation large vessel occlusion (ACLVO).[@R3]

In patients with BAO and other large vessel occlusions (LVOs) of the posterior circulation (PC), indications for mechanical thrombectomy (MT) lack evidence derived from large pivotal thrombectomy trials.[@R5] Intravenous thrombolysis (IVT) is therefore the standard of care in those patients.[@R7] Yet, IVT yields insufficient acute reperfusion rates in patients with BAO.[@R8] Therefore, many patients subsequently deteriorate clinically and tend to have poor outcomes if reperfusion is not achieved.[@R8]

Recanalization rates of MT were reported to be lower than with AC occlusions and procedure time longer.[@R15] Furthermore in BAO, poor outcome despite successful recanalization by MT was reported to occur more frequently---a phenomenon termed futile recanalization (FR) (modified Rankin Scale (mRS) score 4--6 despite complete recanalization).[@R15] In this setting, ethics and patient preferences are taken into account when considering the risk of subjecting patients to a treatment that may avoid death but instead creates long-term dependence.[@R19] Efforts have been made to identify predictors of FR in BAO---namely, stroke severity on admission, amount of radiological lesion on baseline MRI or CT, respiratory instability, and collateral quality.[@R16] Despite those efforts, the rates of long-term dependence were reported to be around 30%[@R23] after MT in BAO.

Although several studies have reported predictors of outcome after endovascular therapy in patients with BAO, few studies have focused solely on MT. Furthermore, reports were limited by small numbers of patients, non-transparent patient selection, heterogeneous endovascular treatments, and inclusion of patients with more distal occlusions.

The aims of this study were hence to compare patients' outcome, the relative merits of achieving recanalization, predictors of FR, and procedural safety between BAO and ACLVO MT, and predictors of FR in BAO.

Methods {#s2}
=======

Details of the BEYOND-SWIFT Registry are in the public domain (NCT03496064) and have been published previously.[@R24] Briefly, the registry is a retrospective, multicenter, non-randomized observational study designed to investigate the safety and efficacy of a Medtronic market-released neurothrombectomy device (applied as the initial device used for interventions) in patients with acute ischemic stroke who do not fulfill treatment eligibility requirements according to the current guidelines. An overview of the patients included in the registry, the follow-up data for each center, and ethical approval procedures can be found in online [supplementary table I](#SP1){ref-type="supplementary-material"}. Ethical approval was obtained in Bern for pooling and analyses of the registry data (KEK Bern, Bern, Switzerland ID 2018--00766).
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Most patients included in the registry (n=2046) were treated for large-vessel anterior circulation strokes (n=1832). Of the patients treated for BAO (n=165), 152 (92.1%) had documented 90-day follow-up. Selection criteria for performing MT in BAO were center-specific and are presented in online [supplementary table 5](#SP1){ref-type="supplementary-material"}.

Variables and image analysis {#s2a}
----------------------------

Local investigators categorized the site of LVO into vertebral artery, basilar artery, or first/second segment of the posterior cerebral artery (P1/P2) occlusions. For the main analysis we compared patients with BAO with those with iICA/carotid-T/M1-occlusions. Either the operator at each center or an independent research fellow rated the postprocedural modified Thrombolysis in Cerebral Infarction (mTICI) score (see online [supplementary table I](#SP1){ref-type="supplementary-material"}). mTICI 2b was rated as reperfusion of at least 50% of the initially occluded target vessel territory, according to modifications of the TICI scale.[@R25] For clinical outcome evaluation, we assessed 3-month functional outcomes using the mRS score in routinely scheduled clinical visits or standardized telephone interviews organized at each center. FR was defined as successful recanalization in patients with mRS score 4--6 at 90 days.[@R20] Worsening in the National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points between the admission NIHSS score and the score 24 hours later, and not attributable to an intracerebral hemorrhagic event was defined as non-hemorrhagic worsening.[@R26]

Statistical analysis {#s2b}
--------------------

Univariate comparisons between patients with BAO or ACLVO, between patients with favorable outcome (mRS score 0--2) and patients with unfavorable outcome (mRS score 3--6), as well as between patients with futile and non-futile recanalization were made using standard statistical measures (Fisher's exact test for categorical variables, Mann--Whitney U test for non-normally continuous or ordinally scaled variables, and Welsch's t-test for independent normally distributed data).

The primary endpoint of this analysis was favorable outcome at 90 days (mRS score 0--2) in BAO versus ACLVO according to multivariate analysis. Secondary outcomes consisted of rate of successful recanalization, FR, all-cause mortality at day 90, overall complication rate, and symptomatic intracerebral hemorrhage (sICH), which was assessed at each center by applying the ECASS II criteria, although they were originally established for AC strokes. The association between BAO *versus* ACLVO with all of the previously listed outcome parameters was hence assessed using multivariable logistic regression with adjustments for the following confounders: age (continuous), prestroke independence (categorical), NIHSS score on admission (ordinal, adjusted odds ratio (aOR) per point increase), systolic blood pressure (metric, aOR per mm Hg increase), known onset (categorical), risk factor hypertension (categorical), risk factor smoking (categorical), risk factor previous stroke (categorical), risk factor diabetes (categorical), type of admission imaging (CT vs MRI, categorical), IVT (categorical), and time from symptom onset to admission (metric, aOR per minute increase). The adjustments were made according to significant baseline differences in univariate analysis, except for admission glucose levels and history of coronary heart disease since too many data items were missing.

A potential difference in the relative merits of achieving successful recanalization between BAO and ACLVO was evaluated with interaction terms. For this comparison, we assessed the relative effect of successful recanalization on various dichotomizations of functional outcome and safety parameters using multivariable logistic regression with adjustments for the following prespecified confounders: age (continuous), sex (categorical), NIHSS score on admission (ordinal, aOR per point increase) and IVT (categorical). The adjustments for this analysis were made according to a clinical assumption of the main confounders as the restricted number of patients without successful recanalization limited the number of variables that could be included.

Results {#s3}
=======

Baseline {#s3a}
--------

For baseline differences, the 165 patients with BAO were younger, more often male, more often transferred from other hospitals, had more severe symptoms on admission, higher glucose on admission, less often anticoagulation pretreatment, less often hypertension, less often dyslipidemia, other TOAST etiology, and MRI was less often performed as the initial imaging modality ([table 1](#T1){ref-type="table"}) as compared with ACLVO. Furthermore, time from symptom onset to groin puncture was longer in BAO than in ACLVO (median 300 min vs 225 min, p\<0.001).

###### 

Baseline characteristics comparing patients with basilar artery occlusion and patients with large vessel occlusion in the anterior circulation

  Characteristics                                                    BAO (n=165)                 ACLVO (intracranial carotid artery, carotid-T, M1) (n=1574)   P value
  ------------------------------------------------------------------ --------------------------- ------------------------------------------------------------- ---------
  Clinical items                                                                                                                                               
   Age (years)                                                       70 (59--80), N=165          73 (61--82), N=1574                                           0.019
   Transfer from another hospital                                    80/165 (48.5%)              561/1572 (35.7%)                                              0.002
   Sex (female)                                                      69/165 (41.8%)              810/1574 (51.5%)                                              0.022
   NIHSS on admission                                                18 (8--30), N=155           17 (12--20), N=1558                                           0.046
   Prestroke independence                                            149/164 (90.9%)             1446/1556 (92.9%)                                             0.341
   Blood pressure systolic (mm Hg)                                   148 (SD 31), N=86           150 (SD 28), N=1141                                           0.413
   Blood pressure diastolic (mm Hg)                                  78 (SD 16), N=86            82 (SD 20), N=1139                                            0.097
   Admission glucose (mmol/L)                                        7.5 (6.4--9.7), N=93        6.6 (5.8--8.1), N=1181                                        \<0.001
   Wake-up stroke                                                    13/161 (8.1%)               123/1451 (8.5%)                                               1.000
   TOAST etiology                                                                                                                                              0.008
    Large artery                                                     37/163 (22.7%)              205/1546 (13.3%)                                              
    Cardioembolic                                                    64/163 (39.3%)              733/1546 (47.4%)                                              
    Other specific etiology                                          12/163 (7.4%)               101/1546 (6.5%)                                               
    Unknown etiology                                                 50/163 (30.7%)              507/1546 (32.8%)                                              
  Medication                                                                                                                                                   0.058
   Antiplatelet                                                                                                                                                
    Monotherapy                                                      36/154 (23.4%)              430/1463 (29.4%)                                              
    Dual therapy                                                     0 (0%)                      26/1463 (1.8%)                                                
   Statin                                                            32/142 (22.5%)              395/1300 (30.4%)                                              0.053
   Anticoagulation                                                                                                                                             0.014
  VKA                                                                10/154 (6.5%)               180/1464 (12.3%)                                              
    NOAC                                                             2/154 (1.3%)                64/1464 (4.4%)                                                
  Risk factors                                                                                                                                                 
   Diabetes                                                          23/163 (14.1%)              271/1555 (17.4%)                                              0.326
   Arterial hypertension                                             87/163 (53.4%)              1046/1553 (67.4%)                                             \<0.001
   Dyslipidemia                                                      60/161 (37.3%)              788/1547 (50.9%)                                              0.001
   Smoking                                                           47/153 (30.7%)              428/1499 (28.6%)                                              0.574
   Previous stroke                                                   17/159 (10.7%)              209/1565 (13.4%)                                              0.389
   Coronary artery disease                                           17/83 (20.5%)               235/1131 (20.8%)                                              1.000
  Type of imaging                                                                                                                                              0.010
    MRI                                                              42/165 (25.5%)              994/1544 (64.4%)                                              
    CT                                                               123/165 (74.5%)             550/1544 (35.6%)                                              
  Treatment                                                                                                                                                    
   IVT use                                                           71/165 (43.0%)              779/1574 (49.5%)                                              0.120
   Time from onset of symptoms to IVT needle (min)                   165 (113--210), N=39/71     120 (83--165), N=437/779                                      0.003
   Time from onset of symptoms to admission in stroke center (min)   228 (IQR 121--369), N=132   143 (71--245), N=1380                                         \<0.001
   Time from onset of symptoms to groin puncture (min)               300 (IQR 211--480), N=133   225 (165--315), N=1346                                        \<0.001

ACLVO, anterior circulation large-vessel occlusion; BAO, basilar artery occlusion; IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; NOAC, non-vitamin K antagonist oral anticoagulants;TOAST, Trial of ORG 10172 in Acute Stroke Treatment; VKA, vitamin K antagonist. Difference in numbers of observations and total numbers of patients in each group due to missing data items.

Technical efficacy {#s3b}
------------------

Comparison of MT in patients with BAO and patients with ACLVO showed that the procedure was more often effective in BAO, with achievement of a mTICI 3 recanalization in 61.8% and a mTICI 2b/3 in 90.3% of patients requiring fewer maneuvers (p=0.002). Groin puncture to recanalization intervals in patients with BAO were similar to those in ACLVO (median 45 min vs 47 min, p=0.824). However, more intracranial stents were used in patients with BAO (17.0% vs 2.3%, p\<0.001) and longer times from symptom onset to groin-puncture (300 min vs 225 min, p\<0.001) were noted, probably because interventions usually required general anesthesia (88.2% vs 54.9%, p\<0.001) ([table 2](#T2){ref-type="table"}). Also on multivariate analysis with adjustments for baseline differences, MT in BAO was associated with higher odds of achieving TICI 3 (aOR=2.004, 95% CI 1.227 to 3.274, p=0.005) and successful recanalization ≥TICI 2b (aOR=2.740, CI 1.145 to 6.554).

###### 

Safety and efficacy data comparing patients with basilar artery occlusion and patients with large vessel occlusion in the anterior circulation

                                                      MT of BAO (n=165)                                                                      MT of ACLVO (n=1574)                                                           P value
  --------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------
  Efficacy                                                                                                                                                                                                                  
   mTICI 3                                            102/165 (61.8%)                                                                        706/1571 (44.9%)                                                               \<0.001
   mTICI ≥2b                                          149/165 (90.3%)                                                                        1299/1571 (82.7%)                                                              0.011
   Time from groin puncture to recanalization (min)   45 (30--81), N=153                                                                     47 (30--75), N=1471                                                            0.824
   General anesthesia                                 142/161 (88.2%)                                                                        792/1442 (54.9%)                                                               \<0.001
   Additional intra-arterial thrombolytic agents      18/160 (11.3%)                                                                         112/1443 (7.8%)                                                                0.127
   Maneuver count                                     1 (IQR 1--2), N=101                                                                    2 (1--3), N=1106                                                               0.002
   Intracranial stenting                              28/165 (17.0%)                                                                         36/1572 (2.3%)                                                                 \<0.001
   Extracranial stenting                              13/165 (7.9%)                                                                          182/1572 (11.6%)                                                               0.194
  Safety                                                                                                                                                                                                                    
   sICH ECASS II definition                           8/165 (4.8%)                                                                           98/1562 (6.3%)                                                                 0.608
   Systemic bleeding                                  1/39 (2.6%)                                                                            21/637 (3.3%)                                                                  1.000
   Craniectomy                                        4/161 (2.5%)                                                                           51/1448 (3.5%)                                                                 0.649
   Any interventional complication                    18/165 (10.9%)                                                                         198/1572 (12.6%)                                                               0.620
   Complications                                      Two vasospasmsFive dissectionsThree perforationsTwo emboli to new territorySix other   51 vasospasms37 dissections21 perforations59 emboli to new territory32 other   

ACLVO, anterior circulation large vessel occlusion; BAO, basilar artery occlusion; MT, mechanical thrombectomy; mTICI, modified Thrombolysis in Cerebral Infarction; sICH, symptomatic intracranial hemorrhage according to the European Cooperative Acute Stroke Study II definition. Difference in numbers of observations and total numbers of patients in each group due to missing data items.

Safety {#s3c}
------

Safety endpoints, including sICH, systemic bleeding, craniectomy, and complication rates, were less frequent in patients with BAO than in patients with ACLVO ([table 2](#T2){ref-type="table"}), but the difference did not reach statistical significance. Also on multivariate analysis, MT in BAO as compared with ACLVO was not associated with either sICH (aOR=0.773, 95% CI 0.228 to 2.618) or mortality (aOR=1.612, 95% CI 0.891 to 2.918). However, patients with MT in BAO more often had postinterventional non-hemorrhagic worsening (aOR=2.797, CI 1.366 to 5.726) than in ACLVO.

Outcome {#s3d}
-------

Patients with BAO had worse outcomes than patients with ACLVO, as shown by a lower rate of moderate outcome (mRS score 0--3, 46.1% vs 56.7%, p=0.013) and a higher mortality rate (36.2% vs 24.4%, p=0.002), although rates of excellent functional outcome (mRS score 0--1, 25.0% vs 27.3%, p=0.631) and favorable outcome (mRS score 0--2, 36.2% vs 42.9%, p=0.120) were comparable in an unadjusted analysis (online [supplementary table 2](#SP1){ref-type="supplementary-material"}).

Baseline differences of patients with favorable outcome (mRS score 0--2) and unfavorable outcome (mRS score 3--6) can be found in online [supplement table 3](#SP1){ref-type="supplementary-material"} and favoured neither BAO nor ACLVO. After adjusting for baseline differences, there was no significant difference in excellent (aOR=0.893, 95% CI 0.478 to 1.669), favorable (primary outcome, aOR=0.986, 95% CI 0.553 to 1.758, [figure 1](#F1){ref-type="fig"}) and moderate functional outcome at 90 days (aOR=0.692, 95% CI 0.396 to 1.121).

![Comparison of outcomes of mechanical thrombectomy (MT) in posterior versus anterior circulation. Adjusted OR of MT in basilar artery occlusion versus anterior circulation large vessel occlusion for outcome parameters in the binary multivariable logistic regression analysis, adjusting for age, National Institutes of Health Stroke Scale score on admission, systolic blood pressure, prestroke independence, known onset, diabetes, arterial hypertension, smoking, previous stroke, imaging type, intravenous thrombolysis, and time from onset to admission. mRS, modified Rankin scale; sICH, symptomatic intracranial hemorrhage; TICI, Thrombolysis in Cerebral Infarction.](neurintsurg-2018-014516f01){#F1}

In conclusion, patients with BAO had worse outcomes on univariate analysis, but after adjustment for baseline differences, we could observe no significant differences of outcome of MT in BAO vs ACLVO, except an increased occurrence of FR.

FR was found more often in BAO than in ACLVO (aOR=2.146, CI 1.267 to 3.633). Factors associated with FR in univariate analysis were older age, higher stroke severity, coronary artery disease, higher maneuver count, and intracranial stenting ([table 3](#T3){ref-type="table"}). Prestroke dependence, lower posterior circulation Alberta Stroke Program Early CT Score (pcASPECTS), longer time from groin puncture to recanalization and administration of additional intra-arterial thrombolytic agents showed a trend towards association with FR.

###### 

Baseline and interventional differences of patients with futile and non-futile reperfusion

  ----------------------------------------------------------------------------------------------------------------------------------
                                                         Futile recanalization (n=70)   Non-futile recanalization (n=79)   P value
  ------------------------------------------------------ ------------------------------ ---------------------------------- ---------
  Clinical items                                                                                                           

   Age (years)                                           74 (63--81), N=70              67 (57--79), N=79                  0.025

   Transfer from another hospital                        34/70 (48.6%)                  37/79 (46.8%)                      0.870

   Sex (female)                                          34/70 (48.6%)                  30/79 (38.0%)                      0.246

   NIHSS score on admission                              21 (12--36), N=65              12 (6--23), N=75                   0.002

   Prestroke independence                                60/70 (85.7%)                  75/79 (94.9%)                      0.089

   Blood pressure systolic (mm Hg)                       154 (SD 32), N=41              144 (SD 28), N=39                  0.170

   Blood pressure diastolic (mm Hg)                      78 (SD 17), N=41               78 (SD 15), N=39                   0.840

   Admission glucose (mmol/L)                            7.6 (6.3--9.3), N=45           7.4 (6.4--9.8), N=41               0.959

   Noticed symptom onset                                 50/70 (71.4%)                  62/79 (78.5%)                      0.347

   Wake up                                               7/70 (10.0%)                   5/77 (6.5%)                        0.551

   In-hospital stroke                                    2/70 (2.9%)                    0/79                               0.219

  Medication                                                                                                               0.417

   Antiplatelet                                                                                                            

    Monotherapy                                          17/67 (25.4%)                  14/75 (18.7%)                      

    Dual therapy                                         0/67                           0/75                               

   Statin                                                15/63 (23.8%)                  12/69 (17.4%)                      0.394

   Anticoagulation                                                                                                         0.401

    None                                                 63/67 (94.0%)                  69/75 (92.0%)                      

    VKA                                                  4/67 (6.0%)                    4/75 (5.3%)                        

    NOAC                                                 0/67                           2/75 (2.7%)                        

  Risk factors                                                                                                             

   Diabetes                                              10/69 (14.5%)                  9/79 (11.4%)                       0.628

   Arterial hypertension                                 36/69 (52.2%)                  40/79 (50.6%)                      0.870

   Dyslipidemia                                          26/67 (38.8%)                  26/79 (32.9%)                      0.491

   Smoking                                               16/65 (24.6%)                  25/74 (33.8%)                      0.267

   Previous stroke                                       8/67 (11.9%)                   8/79 (10.1%)                       0.794

   Coronary artery disease                               11/35 (31.4%)                  4/40 (10.0%)                       0.040

   TOAST etiology\                                                                                                         0.286
                                                                                                                           

    Large artery                                         13/69 (18.8%)                  21/79 (26.6%)                      

    Cardioembolic                                        27/69 (39.1%)                  33/79 (41.8%)                      

    Other specific etiology                              4/69 (5.8%)                    7/79 (8.9%)                        

    Unknown etiology                                     25/69 (36.2%)                  18/79 (22.8%)                      

  Type of imaging                                                                                                          1.000

   MRI                                                   16/70 (22.9%)                  19/79 (24.1%)                      

   CT                                                    54/70 (77.1%)                  60/79 (75.9%)                      

   pcASPECTS                                             7 (5--9), N=25                 8 (7--9), N=24                     0.076

  Treatment                                                                                                                

   IVT use                                               29/70 (41.4%)                  33/79 (41.8%)                      1.000

   Time from onset of symptoms to IVT needle (min)       165 (117--225), N=21/29        178 (109--228), N=16/33            0.914

   Time from onset of symptoms to admission (min)        240 (122--446), N=55           222 (112--335), N=67               0.231

   Time from onset of symptoms to groin puncture (min)   305 (211--539), N=55           300 (200--450), N=67               0.365

   Time groin to recanalization (min)                    47 (34--86), N=67              41 (28--68), N=76                  0.096

   General anesthesia                                    61/70 (87.1%)                  68/77 (88.3%)                      1.000

   Additional intra-arterial thrombolytic agents         11/70 (15.7%)                  4/76 (5.3%)                        0.055

   Balloon-guiding catheter                              2/70 (2.9%)                    7/76 (9.2%)                        0.169

   Intracranial stent                                    17/70 (24.3%)                  7/79 (8.9%)                        0.014

   Extracranial stent                                    3/70 (4.3%)                    8/79 (10.1%)                       0.219

   Any interventional complication                       7/70 (10.0%)                   6/79 (7.6%)                        0.773

   Maneuver                                              1 (1--2), N=45                 1 (1--2), N=50                     0.016\*

   sICH ECASS II                                         2/70 (2.9%)                    2/79 (2.5%)                        1.000
  ----------------------------------------------------------------------------------------------------------------------------------

\*Maneuver count higher in futile recanalization.

IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; NOAC, non-vitamin K antagonist oral anticoagulants; pcASPECTS, posterior circulation Alberta Stroke Program Early CT Score; sICH, symptomatic intracranial hemorrhage according to the European Cooperative Acute Stroke Study II definition; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; VKA, vitamin K antagonist. Difference in numbers of observations and total numbers of patients in each group due to missing data items.

On unadjusted analysis, better outcomes were observed in patients with successful recanalization of BAO (online [supplement table 4](#SP1){ref-type="supplementary-material"}) as compared with patients without successful recanalization. The relative benefit of achieving successful recanalization for various dichotomizations of the mRS scale, mortality, and sICH were comparable between patients presenting with recanalization of BAO and ACLVO according to multivariable binary logistic regression analysis, adjusting for prespecified confounders outlined in the methods section ([figure 2](#F2){ref-type="fig"}). However, significantly higher rates of independence at 3 months were found only in the cohort of patients presenting with ACLVO.

![Effect of successful reperfusion on outcomes stratified for posterior versus anterior circulation. Adjusted OR of achieving successful recanalization (modified Thrombolysis in Cerebral Infarction ≥2b/3) for outcome parameters stratified for patients with basilar artery occlusion versus anterior circulation. Notice the broad CIs in the posterior circulation due to the small number of patients in whom recanalization could not be achieved. Numbers indicate the p value for interaction of IV thrombolysis and successful recanalization in the binary multivariable logistic regression analysis, including age, sex, National Institutes of Health Stroke Scale score on admission, and IV thrombolysis. BAO, basilar artery occlusion; mRS, modified Rankin scale; sICH, symptomatic intracranial hemorrhage.](neurintsurg-2018-014516f02){#F2}

In successfully recanalized BAO patients (TICI ≥2b, n=149), excellent recanalization (TICI 3, n=102) approached significance to increase the odds of a favorable outcome (mRS 0--2) at day 90 (aOR=2.177, 95% CI 0.923 to 5.135) and decreased the odds of all-cause mortality at day 90 (aOR=0.408, 95% CI 0.177 to 0.937).

Discussion {#s4}
==========

This registry-based retrospective analysis of patients with BAO treated with stent-retriever MT has the following main findings: (1) In comparison with patients presenting with ACLVO, interventional procedures in patients with BAO were more often technically effective and equally safe as regards mortality and sICH. (2) FR occurred more frequently in BAO, and predictors of FR included age, stroke severity, maneuver count, and intracranial stenting. (3) Patients with MT in BAO had worse functional outcome than in ACLVO on univariate analysis, but after multivariable adjustment, this difference was non-significant. (4) Successful recanalization in patients with BAO had similar associations with lower mortality, lower rates of sICH, and functional outcome as seen in ACLVO.

The recanalization rate of 90.3% in BAO from our study is in line with recent MT observational studies,[@R27] although it is slightly higher than in other systematic reviews, which included earlier studies[@R10] and recent registries.[@R15] Advances in MT technique, operator adjudication,[@R29] use of TICI score in PCLVO[@R30] in our registry, and different patient selection probably best explain the differences observed.

The rate of complications in patients with BAO was 10.9%, which was similar to rates previously reported[@R31] and matched the frequency of complications seen in patients presenting with ACLVO.[@R31] Serious complications observed were three artery perforations with one associated death. Patients with unsuccessful recanalization had a higher complication rate (31.3% vs 8.7%, p=0.018).

Irrespective of treatment modalities, patients with BAO more often have a deleterious course than their counterparts presenting with ACLVO.[@R2] The mortality rate of 36.2% is in line with the published data.[@R17] In accordance with previous data, we found a higher chance for FR in BAO than in ACLVO (47% vs 34%, p=0.002).[@R15] Regarding factors associated with FR, our data confirm previously reported preinterventional factors, including age, baseline NIHSS score and lower pcASPECTS. Contrary to the literature, cardioembolic stroke subtype was no predictor of FR in our study. Importantly, we could identify interventional predictors of FR, mainly higher maneuver count and intracranial stenting. After adjusting for confounders, only age, baseline NIHSS score, and intracranial stenting remained significant prognostic factors for FR in our dataset. Together with a lower mortality rate in successfully recanalized patients, the observation of increased FR suggests that by MT, death was avoided but long-term dependence created. Those finding should be included in the discussion to treat or withhold treatment according to patient preferences.

Corroborating our observations about the beneficial effect of successful recanalization, the meta-analyses by Kumar *et al* also reported that mortality was bisected in patients in whom successful recanalization (mTICI 2b or mTICI 3) was achieved.[@R10] Although partially present on unadjusted analysis, the higher rates of moderate, favorable, and excellent functional outcome were not statistically significant after adjustment for confounders when recanalization was achieved in BAO, although this could be shown by others.[@R14] The small number of patients in whom recanalization could not be achieved was associated with broad confidence intervals, which probably explains the lack of statistical significance. More importantly, the effect of achieving successful recanalization with respect to mortality rates and sICH was independent of IVT administration. Sensitivity analysis disclosed no interaction between IVT and recanalization success.

It is noteworthy that excellent recanalization (TICI 3) was more beneficial for all-cause mortality at day 90 compared with successful recanalization (TICI ≥2b), which could be also shown in ACLVO.[@R35] Therefore, also in BAO, efforts should be made to improve the quality of recanalization by preventing or treating distal emboli.[@R38]

Kumar *et al* concluded that the significant treatment effect of recanalization, confirmed by observational data and meta-analyses in this severe disease, would make a randomized controlled trial (RCT) to compare MT and the best medication-based treatment unethical.[@R10] However, at least two such RCTs are currently being conducted.[@R39] In our opinion, the most relevant question is not whether or not to treat patients with BAO with MT, but rather in which patients recanalization would be futile or cause long-term dependence. Therefore, RCTs comparing patient selection strategies with advanced imaging techniques and concomitant medical therapy are urgently warranted. Possible predictors for good outcome including stroke risk factors, stroke severity (NIHSS score), age, respiratory stability, thrombus length, atherosclerotic stenosis versus embolic occlusion, and collateral status have been published.[@R14] They should be combined in a study protocol of patient selection in BAO to minimize the incidence of futile recanalization.

Limitations {#s4a}
-----------

This is a single-arm multicenter retrospective registry, which has associated limitations. No comparison with patients treated with medical management only was performed, and patient selection for MT was center-specific. Several factors, including final mTICI score and initial pcASPECTS, were not adjudicated by a core laboratory and the exact location of BAO (proximal, middle, distal portion) was unknown. Data quality was incomplete for important predictors of outcome, such as collateral quality and pcASPECTS. Subgroup analyses were generally confined to small cohorts, which introduces a large uncertainty of the presented effects, as indicated by relatively wide confidence intervals.

Conclusion {#s5}
==========

In selected patients treated with MT, similar outcomes can be achieved in BAO and ACLVO. Patients with BAO in whom recanalization could be achieved, had lower mortality and rate of sICH than those with unsuccessful recanalization, without effect heterogeneity in comparison with ACLVO. The aim of MT should be complete recanalization. RCTs comparing patient selection and interventional strategies to avoid futile interventions seem warranted.
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